The NHS has set an ambitious goal to be the worlds first net zero national health service with clear goals to achieve before 2040.2
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
One part of delivering GSK’s commitment to have a net zero impact on climate and net positive impact on nature by 2030.
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA.3
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2022 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
The Ellipta range was developed in collaboration with
March 2022 | PM-GB-FVU-WCNT-210010 (V3.0)